Literature DB >> 12911521

Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14.

Marília S Almeida1, Humberto Torloni, Paulo Lee-Ho, Monica M Vilar, Nilton Thaumaturgo, Andrew J G Simpson, Miriam Tendler.   

Abstract

Fasciola hepatica is the causative agent of fasciolosis in many areas in America, Europe, Africa, Asia and Australia. There is an urgent need for improved methods to control the parasite's transmission. We describe the use of an experimental vaccine based on a recombinant antigen cloned from another parasite, Schistosoma mansoni (Sm14), that induces high levels of cross protection in mice against both S. mansoni and F. hepatica. Sheep and mice vaccinated with Sm14 were significantly protected against challenge infection with metacercariae of Fasciola hepatica and were completely free of the histopathological hepatic damage related to liver fluke infection. The vaccine will provide a valuable new tool to aid in transmission control of this economically important disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911521     DOI: 10.1046/j.1365-3024.2003.00619.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  10 in total

1.  1H, 15N and 13C resonance assignments of the apo Sm14-M20(C62V) protein, a mutant of Schistosoma mansoni Sm14.

Authors:  Thelma A Pertinhez; Maurício L Sforça; Adriana C Alves; Celso R R Ramos; Paulo L Ho; Miriam Tendler; Nilson I T Zanchin; Alberto Spisni
Journal:  J Biomol NMR       Date:  2004-08       Impact factor: 2.835

2.  Effect of regulatory T cells on the efficacy of the fatty acid-binding protein vaccine against Schistosoma japonicum.

Authors:  Chun-Lian Tang; Rong-Hui Zhang; Zhi-Ming Liu; Huang Jin; Long He
Journal:  Parasitol Res       Date:  2019-01-04       Impact factor: 2.289

3.  Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model.

Authors:  Shereen F Mossallam; Eglal I Amer; Radwa E Ewaisha; Amal M Khalil; Hamida M Aboushleib; Mohammed Bahey-El-Din
Journal:  BMC Infect Dis       Date:  2015-03-24       Impact factor: 3.090

Review 4.  Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant.

Authors:  Miriam Tendler; Marilia Almeida; Andrew Simpson
Journal:  Front Immunol       Date:  2015-05-12       Impact factor: 7.561

5.  Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep.

Authors:  Rafael Zafra; Leandro Buffoni; Raúl Pérez-Caballero; Verónica Molina-Hernández; María T Ruiz-Campillo; José Pérez; Álvaro Martínez-Moreno; Francisco J Martínez Moreno
Journal:  Vet Res       Date:  2021-01-28       Impact factor: 3.683

6.  Quantitation of cytokine mRNA by real-time RT-PCR during a vaccination trial in a rabbit model of fascioliasis.

Authors:  Ana M Espino; Francheska Rivera
Journal:  Vet Parasitol       Date:  2009-12-22       Impact factor: 2.738

7.  Gene expression patterns during adaptation of a helminth parasite to different environmental niches.

Authors:  Emmitt R Jolly; Chen-Shan Chin; Steve Miller; Mahmoud M Bahgat; K C Lim; Joseph DeRisi; James H McKerrow
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

8.  Gene discovery for the carcinogenic human liver fluke, Opisthorchis viverrini.

Authors:  Thewarach Laha; Porntip Pinlaor; Jason Mulvenna; Banchob Sripa; Manop Sripa; Michael J Smout; Robin B Gasser; Paul J Brindley; Alex Loukas
Journal:  BMC Genomics       Date:  2007-06-22       Impact factor: 3.969

Review 9.  Fasciola and fasciolosis in ruminants in Europe: Identifying research needs.

Authors:  N J Beesley; C Caminade; J Charlier; R J Flynn; J E Hodgkinson; A Martinez-Moreno; M Martinez-Valladares; J Perez; L Rinaldi; D J L Williams
Journal:  Transbound Emerg Dis       Date:  2017-10-06       Impact factor: 5.005

Review 10.  Schistosomiasis vaccine development: update on human clinical trials.

Authors:  Adebayo J Molehin
Journal:  J Biomed Sci       Date:  2020-01-22       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.